相关实验视频
Updated: Jan 9, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
评估实时连续血糖监测器对药剂师对糖化血红蛋白干预的添加
Alexandra DeBoest1, Chelsea Holley1, Megan Hickey1
1Institute, City, State, USA.
概括
使用实时连续血糖监测器 (rtCGMs) 的药剂师干预显著改善了2型糖尿病患者的糖化血红蛋白 (HbA1c) 水平,与标准护理相比. 这种方法增强了糖尿病管理协议,以获得更好的患者结果.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 数字健康数字健康
背景情况:
- 2型糖尿病的管理需要持续的监测和干预.
- 尽管存在管理协议,但低于最佳的血糖控制是常见的.
- 药剂师主导的干预对于改善患者的治疗结果至关重要.
研究的目的:
- 评估药剂师干预与实时连续血糖监测器 (rtCGMs) 结合对HbA1c水平的影响.
- 在2型糖尿病患者中,比较rtCGMs加标准护理与单独标准护理的有效性.
- 评估两个研究组中药剂师与患者相互作用的数量.
主要方法:
- 一项涉及2型糖尿病患者和HbA1c ≥9%的基础胰岛素的比较研究.
- 两个组:标准护理 (SOC) 与药剂师干预相比,SOC 与药剂师干预加上Dexcom G6 rtCGMs.
- 主要结果:90天后HbA1c的变化;次要结果:药剂师接触点的数量.
主要成果:
- 与SOC组 (2.05%) (P=0.0165) 相比,rtCGM组显示出明显更大的平均HbA1c降低 (2.94%).
- 这项研究包括57名患者 (30名SOC,27名rtCGM).
- 药剂师接触点的差异没有达到统计学意义 (P=0.1413).
结论:
- 增加标准的糖尿病管理协议与rtCGMs导致更大的HbA1c降低2型糖尿病.
- 对于药剂师来说,rtCGM可以成为管理复杂糖尿病病例的宝贵工具.
- 进一步的研究可能会探索通过rtCGM技术优化药剂师接触点.
相关概念视频
01:15Hypoglycemia and Glucagon
778
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
778
01:14SBAR II: Application of SBAR
5.6K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
5.6K
01:15Diabetes: Management and Pharmacotherapy
848
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
848
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559